A Phase I/II, Randomized, Double-blind, Comparator-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of TLC590 for Postsurgical Pain Management Following Inguinal Hernia Repair

Trial Profile

A Phase I/II, Randomized, Double-blind, Comparator-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of TLC590 for Postsurgical Pain Management Following Inguinal Hernia Repair

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Ropivacaine (Primary) ; Ropivacaine
  • Indications Postoperative pain
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 18 Jul 2018 Status changed from planning to not yet recruiting.
    • 09 Jul 2018 According to a Taiwan Liposome Company media release, Clearance received from the U.S. Food and Drug Administration (FDA) for the TLC590 Investigational New Drug (IND) applications, allowing Phase I/II trials to proceed in the US.
    • 09 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top